osu 2014 asco review savvides pres head & neck
DESCRIPTION
Ohio State's 2014 ASCO Review Head and Neck Cancer Update Presentation by Dr. Panayiotis (Panos) SavvidesTRANSCRIPT
ASCO Review: H&N Cancer
Panos Savvides, MD PhD MPH
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute 2
ASCO 2014 Review: What’s new in H&N?
Results of SELECT, a lenvatinib phase III clinical trial in Radioactive Iodine Refractory Thyroid Cancer: A new treatment standard? Role of induction chemotherapy in locally advanced
head and neck cancer Italian Induction phase III clinical trial Induction in Nasopharyngeal cancer Treatment de-intensification in Oropharyngeal Cancer
Predictive and prognostic markers to therapy Cetuximab and HPV
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT)
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
Slide 17
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
Study Rationale
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
Study 303: Study Schema
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
Patient Characteristics
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
Primary Endpoint:<br />Kaplan-Meier Estimate of PFS
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
PFS by Previous VEGF-Targeted Therapy
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
PFS Subgroup Analyses
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
Response Rates
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
Best Tumor Response
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
Overall Survival, ITT population
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
Study Medication Exposure
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
Treatment-emergent Adverse Events (TEAEs)
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
Most Frequent Treatment-related Adverse Events (> 20%)
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
TEAEs of Special Interest
Presented By Martin Schlumberger at 2014 ASCO Annual Meeting
Clinical trial comparison DECIDE v SELECT
Presented By A. Colevas at 2014 ASCO Annual Meeting
tumor reduction
Presented By A. Colevas at 2014 ASCO Annual Meeting
Primary endpoint: PFS
Presented By A. Colevas at 2014 ASCO Annual Meeting
Survival: Neither sorafenib nor lenvatinib improve survival in these trials
Presented By A. Colevas at 2014 ASCO Annual Meeting
Toxicity and dosing issues
Presented By A. Colevas at 2014 ASCO Annual Meeting
Lingering questions
Presented By A. Colevas at 2014 ASCO Annual Meeting
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute 24
ASCO 2014 Review: What’s new in H&N?
Results of SELECT, a lenvatinib phase III clinical trial in Radioactive Iodine Refractory Thyroid Cancer: A new treatment standard? Role of induction chemotherapy in locally
advanced head and neck cancer Italian Induction phase III clinical trial Induction in Nasopharyngeal cancer Treatment de-intensification in Oropharyngeal Cancer
Predictive and prognostic markers to therapy Cetuximab and HPV
History of Induction Chemotherapy
Presented By Quynh-Thu Le at 2014 ASCO Annual Meeting
ICT vs. CRT
Presented By Quynh-Thu Le at 2014 ASCO Annual Meeting
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute 27
ASCO 2014 Review: What’s new in H&N?
Results of SELECT, a lenvatinib phase III clinical trial in Radioactive Iodine Refractory Thyroid Cancer: A new treatment standard? Role of induction chemotherapy in locally
advanced head and neck cancer Italian Induction phase III clinical trial Induction in Nasopharyngeal cancer Treatment de-intensification in Oropharyngeal Cancer
Predictive and prognostic markers to therapy Cetuximab and HPV
Slide 7
Presented By Quynh-Thu Le at 2014 ASCO Annual Meeting
Slide 8
Presented By Quynh-Thu Le at 2014 ASCO Annual Meeting
Slide 9
Presented By Quynh-Thu Le at 2014 ASCO Annual Meeting
Trial Comparison
Presented By Quynh-Thu Le at 2014 ASCO Annual Meeting
Slide 11
Presented By Quynh-Thu Le at 2014 ASCO Annual Meeting
Slide 12
Presented By Quynh-Thu Le at 2014 ASCO Annual Meeting
Questions Pertained to the Italian Study
Presented By Quynh-Thu Le at 2014 ASCO Annual Meeting
Overall Survival based on RT quality/volume
Presented By Quynh-Thu Le at 2014 ASCO Annual Meeting
What can we conclude about ICT?
Presented By Quynh-Thu Le at 2014 ASCO Annual Meeting
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute 37
ASCO 2014 Review: What’s new in H&N?
Results of SELECT, a lenvatinib phase III clinical trial in Radioactive Iodine Refractory Thyroid Cancer: A new treatment standard? Role of induction chemotherapy in locally advanced
head and neck cancer Italian Induction phase III clinical trial Induction in Nasopharyngeal cancer Treatment de-intensification in Oropharyngeal Cancer
Predictive and prognostic markers to therapy Cetuximab and HPV
Chemotherapy in NPC
Presented By Quynh-Thu Le at 2014 ASCO Annual Meeting
NCCS Trial Treatment Schema
Presented By Quynh-Thu Le at 2014 ASCO Annual Meeting
NCCS Outcomes
Presented By Quynh-Thu Le at 2014 ASCO Annual Meeting
Why is NCCS Trial Negative
Presented By Quynh-Thu Le at 2014 ASCO Annual Meeting
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute 42
ASCO 2014 Review: What’s new in H&N?
Results of SELECT, a lenvatinib phase III clinical trial in Radioactive Iodine Refractory Thyroid Cancer: A new treatment standard? Role of induction chemotherapy in locally advanced
head and neck cancer Italian Induction phase III clinical trial Induction in Nasopharyngeal cancer Treatment de-intensification in Oropharyngeal
Cancer Predictive and prognostic markers to therapy Cetuximab and HPV
Risk Group Definition base on HPV, Tobacco use & T/N status – Possible role for dose de-escalation in a patient subgroup
Presented By Quynh-Thu Le at 2014 ASCO Annual Meeting
Slide 28
Presented By Quynh-Thu Le at 2014 ASCO Annual Meeting
Results of E1308
Presented By Quynh-Thu Le at 2014 ASCO Annual Meeting
Endpoint: 2yr PFS and OS
Presented By Quynh-Thu Le at 2014 ASCO Annual Meeting
Questions to address in good risk HPV+ patients
Presented By Quynh-Thu Le at 2014 ASCO Annual Meeting
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute 48
ASCO 2014 Review: What’s new in H&N?
Results of SELECT, a lenvatinib phase III clinical trial in Radioactive Iodine Refractory Thyroid Cancer: A new treatment standard? Role of induction chemotherapy in locally advanced
head and neck cancer Italian Induction phase III clinical trial Induction in Nasopharyngeal cancer Treatment de-intensification in Oropharyngeal Cancer
Predictive and prognostic markers to therapy Cetuximab and HPV
Biomarkers
Presented By Vassiliki Papadimitrakopoulou at 2014 ASCO Annual Meeting
HPV and cetuximab
Presented By Vassiliki Papadimitrakopoulou at 2014 ASCO Annual Meeting
Cetuximab + Chemotherapy in SCCHN
Presented By Vassiliki Papadimitrakopoulou at 2014 ASCO Annual Meeting
SPECTRUM: OS and PFS by arm and p16
Presented By Vassiliki Papadimitrakopoulou at 2014 ASCO Annual Meeting
RT + cetuximab significantly improves LRC and 5-year OS
Presented By Vassiliki Papadimitrakopoulou at 2014 ASCO Annual Meeting
Slide 10
Presented By Vassiliki Papadimitrakopoulou at 2014 ASCO Annual Meeting
Slide 11
Presented By Vassiliki Papadimitrakopoulou at 2014 ASCO Annual Meeting
Interactions between HPV and the EGFR signaling pathway
Presented By Vassiliki Papadimitrakopoulou at 2014 ASCO Annual Meeting
Slide 14
Presented By Vassiliki Papadimitrakopoulou at 2014 ASCO Annual Meeting